Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Operating Leases (2022 - 2025)

Historic Operating Leases for Oncology Institute (TOI) over the last 4 years, with Q3 2025 value amounting to $27.4 million.

  • Oncology Institute's Operating Leases fell 1291.5% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 1291.5%. This contributed to the annual value of $23.2 million for FY2024, which is 1231.97% down from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Operating Leases is $27.4 million, which was down 1291.5% from $28.1 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Operating Leases peaked at $32.6 million during Q2 2023, and registered a low of $18.7 million during Q1 2022.
  • In the last 4 years, Oncology Institute's Operating Leases had a median value of $27.9 million in 2023 and averaged $27.1 million.
  • In the last 5 years, Oncology Institute's Operating Leases soared by 7093.19% in 2023 and then plummeted by 1291.5% in 2025.
  • Quarter analysis of 4 years shows Oncology Institute's Operating Leases stood at $22.1 million in 2022, then increased by 20.06% to $26.5 million in 2023, then decreased by 12.32% to $23.2 million in 2024, then rose by 17.8% to $27.4 million in 2025.
  • Its Operating Leases was $27.4 million in Q3 2025, compared to $28.1 million in Q2 2025 and $28.4 million in Q1 2025.